HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Clinical trials for HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER explained in plain language.
Never miss a new study
Get alerted when new HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER trials appear
Sign up with your email to follow new studies for HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radiation challenge to standard bladder cancer treatment could reduce recurrence and save bladders
Disease control Not yet recruitingThis study compares two approaches for treating high-risk bladder cancer that hasn't spread into the muscle layer. The standard treatment involves surgery followed by BCG immunotherapy placed directly into the bladder, which requires maintenance treatment for up to 3 years and ha…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE3 • Sponsor: The Christie NHS Foundation Trust • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for bladder cancer patients who Can't have major surgery
Disease control Not yet recruitingThis study is testing a new drug called HS-10566 for people with high-risk bladder cancer that hasn't spread into the muscle wall. It's for patients who are not eligible for or refuse surgery to remove their bladder. The research will first find a safe dose and then see how well …
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New bladder cancer drug enters first human trials
Disease control Not yet recruitingThis early-stage study aims to test the safety and determine the right dose of an experimental drug called JL19001 injection for people with high-risk non-muscle invasive bladder cancer. The drug will be tested alone and in combination with the standard BCG treatment. Researchers…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE1 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC